

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

March 15, 2018

Missouri Coalition for Community Behavior Healthcare

221 Metro Drive, Lower Level CEO Room

Jefferson City, MO

Committee Members Present

Conrad Balcer, D.O., Chair
Jennifer Kemp-Oestreich, Pharm D
Laura Kingsley, Pharm D
Morgan Sperry, Pharm D
Pat Bryant, Pharm D

Guest of Committee Member

Katie Boatwright, Pharm D, Drug Information Fellow

Contractors in Attendance:

Joshua Moore, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Rick Pope, Pharm D, Magellan
Geri Roling, Wipro
Chelsea Pendleton, Wipro

Others Attending:

Michael Lafond, Abbvie
Evan Rushing, Alkermes
Brent Fushimi, Arbor
Scott Jones, AstraZeneca
Aaron Shaw, Boehringer Ingelheim
Chi Kohlhoff, Braeburn
Lee Stout, Chiesi
Michele Puyear, Gilead

Brent DePriest, GlaxoSmithKline
Leonard Erskine, Incyte
Paul Bragoli, Indivior
Robert Robey, Indivior
Christy Skibicki, Indivior
Jennifer Davis, Kite
Meghan Kerrigan, Merck
Tom Peddicord, Novartis

MO HealthNet Staff Present:

Stephen Calloway, R.Ph, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Jenna McTeer, RN, Clinical Management
Angela Wilson, Manager, Band I
Frances (Franki) Moseley, Administrative Office Support Assistant
Mitch Ruth, Pharmacy Fiscal Unit Manager
Elizabeth Short, Program Development Specialist
Dr. Timothy Kling, MD, Assistant Medical Director
Lisa E. Smith, Program Development Specialist

Welcome, Introductions and Opening Remarks	Conrad Balcer, Chair, called the meeting to order. Stephen Calloway introduced himself and started the introductions and opening remarks. Pat Bryant introduced a guest, Katie Boatwright, Pharm D, Drug Information Fellow.
Minutes Approval	Minutes of the December 2017 Drug PA meeting were reviewed and approved. The quorum for December was not met and the members that were not present at the December meeting voted to approve Committee actions. Dr. Young-Walker provided her vote prior to the meeting. (See Roll Call Vote) Stephen Calloway stated plans for combining the Drug PA Committee and DUR Board are still pending.
Pharmacy Program/Budget Update	Stephen Calloway presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions that were implemented January 2018. Pending ratification, PDL decisions from December 2017/January 2018 will be implemented April 2018. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	
New Drug Review	Stephen Calloway reviewed the new drug products identified for the quarter October thru December 2017. <ul style="list-style-type: none"> • Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • Public Hearing – No comments were entered. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edits	
Brineura Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the new criteria in this document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Respiratory Monoclonal Antibodies Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the new criteria in this document. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Morphine-Milligram-Equivalent (MME) Accumulation Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the new criteria in this document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)

Preferred Drug List (PDL)	
Actinic Keratosis Agents - Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Androgenic Agents - Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No Comments Entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antibiotics - Inhaled	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antifungals (Onychomycosis Agents) - Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antifungals – Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines – Intranasal	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines – Low Sedating (2nd Generation)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines/Decongestants – Low-Sedating	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines – Ophthalmic	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiparasitics - Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antivirals – Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Atopic Dermatitis Agents (Topical Immunomodulators)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented with a motion to move to modify the edit to change the and /or language to require a topical trial <u>or</u> phototherapy <u>or</u> systemic trial. (See Roll Call Vote)
Benzoyl Peroxide/Antibiotic Combinations – Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. This PDL was changed to reflect addition of Erythromycin in combination with Benzoyl Peroxide. • Public Hearing – No Comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta Adrenergic Agents (Long-Acting)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta Adrenergic Agents – Nebulized	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta Adrenergic Agents (Short Acting)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
COPD Anticholinergic Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids and Rhinitis Agents – Intranasal	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids – Oral Inhaled	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee made a motion to change the criteria to three instead of four and voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids - Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Cough & Cold Products	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Cough & Cold Opioid Combination Products	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. It was also noted that the products should be noted as age 18 and older. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Epinephrine Self-Injectable Products	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Fluoroquinolones - Ophthalmic	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Fluoroquinolones - Otic	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. An edit correction was recommended in the Executive Summary. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Herpes Antivirals – Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Leukotriene Modifiers – Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Mast Cell Stabilizers - Ophthalmic	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
NSAIDs – Ophthalmic	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Pancreatic Enzymes	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. Pancrelipase EC (Generic Zenpep®) will be removed or moved to non-preferred since this product is not available. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Prostaglandin Agonists (Glaucoma Agents)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Psoriasis Agents – Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Psoriasis Agents – Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Retinoids – Topical	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Ulcerative Colitis Agents – Oral	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Ulcerative Colitis Agents – Rectal	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf

Conduent Update	Luke Boehmer, Pharm D, presented the following items for review. The Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's. Dr. Boehmer also presented an updated analysis of the Opioid Edits that included the distinct members over 90 MME and also the number of opioid naïve participants that we currently have over 50 MME without a PA. Lastly, Dr. Boehmer presented the New Drug Summary,
Program Utilization: Top 25 Drugs Summary	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 nd , 3 rd , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Call Center Statistics/ Cyber Access Reports	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to Cyber Access. Reports also detailed the number and type of prescribers and active users on Cyber Access.

Adjourn	<p>The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call)</p> <p>Attendees were advised to check the calendar of events on the MHD website for meeting location changes over the next few months. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, June 21, 2018, from 10am-3pm at the Department of Natural Resources, Lacharette/Nightingale Rooms, 1101 Riverside Drive, Jefferson City, MO.</p>
----------------	--

Roll Call Abbreviations:

- A-Abstain
- R-Ratify
- M-Motion
- S-Second
- Y-Yes to the vote

- Absent
- Alternate

Roll Call Votes March 15, 2018

<u>Member</u>	December 2017 Minutes and Committee Actions	New Drugs	Brineura	Respiratory Monoclonal Antibodies	Morphine- Milligram-Equivalent Accumulation	Actinic Keratosis – Topical	Androgenic - Topical
Conrad Balcer, D.O.	A	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	A	M, Y	S, Y	M, Y	Y	M, Y	S, Y
Laine Young-Walker, M.D.	R, Y						
Morgan Sperry, Pharm D	Y						
Jennifer Kemp-Oestreich, Pharm D	M, Y	S, Y	M, Y	Y	M, Y	Y	Y
Laura Kingsley, Pharm D	S, Y	Y	Y	S, Y	S, Y	S, Y	M, Y

<u>Member</u>	Antibiotics – Inhaled	Antifungals (Onychomycosis) – Oral	Antifungals – Topical	Antihistamines – Intranasal	Antihistamines – Low-Sedating	Antihistamines/Decongestants – Low-Sedating	Antihistamines - Ophthalmic
Conrad Balcer, D.O.	Y	S, Y	Y	Y	S, Y	Y	Y
Pat Bryant, Pharm D	Y	M, Y	Y	S, Y	M, Y	S, Y	M, Y
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M, Y	Y	M, Y	M, Y	Y	Y	Y
Laura Kingsley, Pharm D	S, Y	Y	S, Y	Y	Y	M, Y	S, Y

<u>Member</u>	Antiparasitics – Topical	Antivirals – Topical	Atopic Dermatitis (Topical Immunomodulators)	Benzoyl Peroxide/ Antibiotic Combo – Topical	Beta Adrenergic (Long Acting)	Beta Adrenergic – Nebulized	Beta Adrenergic (Short Acting)
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	S, Y	M, Y	M, Y	M, Y	S, Y	M, Y	Y
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M, Y	Y	Y	Y	Y	S, Y	M, Y
Laura Kingsley, Pharm D	Y	S, Y	S, Y	S, Y	M, Y	Y	S, Y

<u>Member</u>	COPD Anticholinergic	Corticosteroids - Intranasal	Corticosteroids – Oral Inhaled	Corticosteroids – Topical	Cough & Cold Products	Cough & Cold Opioid Combo Products	Epinephrine Self – Injectable Products
Conrad Balcer, D.O.	Y	Y	Y	Y	M, Y	Y	Y
Pat Bryant, Pharm D	M, Y	S, Y	M, Y	Y	Y	S, Y	M, Y
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	Y	Y	S, Y	M, Y	Y	Y	Y
Laura Kingsley, Pharm D	S, Y	M, Y	Y	S, Y	S, Y	M, Y	S, Y

<u>Member</u>	Fluoroquinolones – Ophthalmic	Fluoro quinolones – Otic	Herpes Antivirals – Oral	Leukotriene Modifiers – Oral	Mast Cell Stabilizers – Ophthalmic	NSAIDs – Ophthalmic	Pancreatic Enzymes
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	M, Y	S, Y	M, Y	S, Y	S, Y	S, Y
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M, Y	Y	M, Y	Y	Y	M, Y	Y
Laura Kingsley, Pharm D	S, Y	S, Y	Y	S, Y	M, Y	Y	M, Y

<u>Member</u>	Prostaglandin Agonists – (Glaucoma)	Psoriasis – Oral	Psoriasis – Topical	Retinoids – Topical	Ulcerative Colitis – Agents	Ulcerative Colitis – Rectal	Meeting Adjourned
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	M, Y
Pat Bryant, Pharm D	S, Y	S, Y	Y	M, Y	Y	M, Y	S, Y
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	M, Y	Y	M, Y	Y	M, Y	Y	Y
Laura Kingsley, Pharm D	Y	M, Y	S, Y	S, Y	S, Y	S, Y	Y